Why Does the Market Still Pay a Premium for Bio-Techne with Falling Earnings?

Written by

rummu

in

At first glance, Bio-Techne (NASDAQ: TECH) appears difficult to understand. Over the past decade, revenue has more than doubled, growing from roughly $5 billion to over $12 billion. Yet reported earnings per share have been inconsistent, margins have compressed significantly in recent years, and the stock continues to trade at valuation multiples that seem disconnected […]

You are unauthorized to view this page.

  • Rummu provides data, analysis, and tools for research purposes only. The information presented does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. It does not take into account individual objectives, financial situations, or needs. You are solely responsible for your own investment decisions.

More posts